Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.

IF 2 Q3 ONCOLOGY Cancer research communications Pub Date : 2025-01-01 DOI:10.1158/2767-9764.CRC-24-0287
Georgia Mitsa, Livia Florianova, Josiane Lafleur, Adriana Aguilar-Mahecha, Rene P Zahedi, Sonia V Del Rincon, Mark Basik, Christoph H Borchers, Gerald Batist
{"title":"Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.","authors":"Georgia Mitsa, Livia Florianova, Josiane Lafleur, Adriana Aguilar-Mahecha, Rene P Zahedi, Sonia V Del Rincon, Mark Basik, Christoph H Borchers, Gerald Batist","doi":"10.1158/2767-9764.CRC-24-0287","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>This study provides real-world evidence for DCIS, a disease for which currently no molecular tools or biomarkers exist, and gives an unbiased, comprehensive, and deep proteomic profile, identifying >380 actionable targets.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"138-149"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755405/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: This study provides real-world evidence for DCIS, a disease for which currently no molecular tools or biomarkers exist, and gives an unbiased, comprehensive, and deep proteomic profile, identifying >380 actionable targets.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
临床蛋白质组学揭示了非侵袭性乳腺导管癌的脆弱性,并推动了个性化的治疗策略。
导管原位癌(DCIS)是女性中最常见的非侵袭性乳腺病变类型(80%)。缺乏有效的预后标志物、有限的患者数量和可变的组织质量对诊断、风险分层、患者入组和临床研究结果有重大影响。在这里,我们对50例临床福尔马林固定石蜡包埋活检进行了无标记定量蛋白质组学,验证了来自独立遗传研究的22个假定的生物标志物。我们的综合蛋白质组学表型分析揭示了380多种差异表达蛋白和代谢脆弱性,可以为DCIS和浸润性导管癌(IDC)提供新的治疗策略。由于蛋白质和代谢酶或代谢抑制剂的易药物性质,该研究是临床研究和制药行业的高度兴趣。为了进一步评估我们的发现,并促进我们研究的临床转化,我们开发了一种高度多重靶向的蛋白质组学分析,用于90种与癌症代谢、RNA调节和标志性癌症途径相关的蛋白质,如PI3K/AKT/mTOR和EGFR/RAS/RAF。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells. Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence. The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1